Clinical Trials Logo
  1. Home
  2. Severe Eosinophilic Asthma
  3. NCT03652376

Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma

Severe Eosinophilic Asthma Clinical Trial

Official title:
Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma

Clinical Trial Summary

This study investigates the effect of removing eosinophils from peripheral blood (using treatment with Benralizumab, which is approved for the treatment of severe eosoniphilic asthma) on circulating dendritic cells in patients with severe eosinophilic asthma.

Clinical Trial Description

Phase III clinical trials demonstrated that benralizumab treatment results in a significant decrease in exacerbations and a significant increase in lung function and quality of life in patients with severe eosinophilic asthma. However, the precise underlying mechanisms leading to this clinical benefit of benralizumab treatment are not completely understood. Dendritic cells are key regulators of the adaptive and innate immune system. There is evidence that eosinophils have a direct influence on the function of dendritic cells. In addition, there are multiple indirect interactions between eosinophils and dendritic cells in asthma. However, there is currently no information on the impact of benralizumab treatment and a complete removal of circulating eosinophils on the number and phenotype of human dendritic cells. Benralizumab is chosen for this study because it is the only anti-IL-5 biologic which results in a complete removal of eosinophils from peripheral blood. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03652376
Study type Interventional
Source University of Rostock
Contact Marek Lommatzsch, MD
Phone +49-381-494-0
Email marek.lommatzsch@med.uni-rostock.de
Status Not yet recruiting
Phase Phase 4
Start date September 1, 2018
Completion date December 31, 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Completed NCT02560610 - Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma Phase 2
Recruiting NCT06069310 - Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma
Recruiting NCT04542902 - Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma N/A
Completed NCT05180357 - RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
Active, not recruiting NCT03833141 - Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.
Completed NCT05271526 - Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)
Not yet recruiting NCT06302959 - Clock Proteins as Prognostic Markers
Recruiting NCT05440656 - A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.
Completed NCT04159519 - A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab Phase 4
Completed NCT03907137 - Real World Study With Benralizumab in Severe Asthma in Switzerland
Active, not recruiting NCT04084613 - Mepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece
Completed NCT04126499 - Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain
Recruiting NCT06465485 - STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma Phase 3
Recruiting NCT03739320 - A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma